{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:35:50Z","timestamp":1789036550535,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Central Norway Regional Health Authority Innovation Fund","award":["36292"],"award-info":[{"award-number":["36292"]}]},{"name":"NTNU Health and Life Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the feasibility and safety (primary endpoints), and performance (secondary endpoint) of a new artificial intelligence (AI) software for detecting clinically significant prostate cancer (csPCa) on biparametric MRI (bpMRI) compared to an expert radiologist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this prospective study at St. Olavs Hospital, Norway (December 2023\u2013October 2024), 89 consecutive biopsy-na\u00efve men underwent bpMRI for suspected PCa. Scans were interpreted by a radiologist using PI-RADS v2.1 and a radiomics-based AI software. Biopsies were obtained from all radiologist- and\/or AI-identified lesions. csPCa was defined as ISUP\u2009\u2265\u20092. Feasibility was defined by a &lt; 10% software-failure rate, and safety by the absence of serious adverse device effects (SADEs). Performance was evaluated with ROC, free-response ROC, and precision-recall curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 89 patients eligible for primary endpoints evaluation, the software demonstrated feasibility (7% failure rate) and safety (no SADEs). Among 76 eligible for secondary endpoint evaluation (median age 68 years [IQR: 63\u201373]), csPCa was found in 51% (39\/76). Patient-level, software achieved an area under the ROC curve [95% CI] of 0.90 [0.83, 0.96] versus 0.86 [0.76, 0.93] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.25). At a retrospectively optimized threshold matching the radiologist\u2019s patient-level sensitivity at PI-RADS 3 (0.92), software achieved specificity of 0.68 [0.57, 0.78] versus 0.57 [0.46, 0.68] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.29). Lesion-level, software achieved higher average precision (0.61 [0.52, 0.71] vs. 0.56 [0.46, 0.67]) and lower average false-positive per patient (0.33 [0.22, 0.43] vs. 0.41 [0.30, 0.52]) at the optimized threshold.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The software was feasible and safe, and diagnostic performance showed potential to reduce unnecessary biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>This clinically validated artificial intelligence software enables feasible and safe detection of clinically significant prostate cancer on biparametric MRI, with demonstrated potential to reduce unnecessary biopsies and improve diagnostic accuracy, indicating potential for integration into clinical prostate cancer care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>A fully automated radiomics software for clinically significant prostate cancer detection on biparametric MRI was prospectively clinically validated.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The software demonstrated feasibility and safety, with potential to reduce unnecessary biopsies and improve diagnostic accuracy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The investigated radiomics software has the potential for integration into clinical prostate cancer care.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-025-02199-9","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:33:48Z","timestamp":1769430828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prospective validation of an AI software for detecting clinically significant prostate cancer on biparametric MRI"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1683","authenticated-orcid":false,"given":"Mohammed R. S.","family":"Sunoqrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Segre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A.","family":"Nketiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Davik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torill A. E.","family":"Sj\u00f8bakk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"Lang\u00f8rgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattijs","family":"Elschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone F.","family":"Bathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777","journal-title":"N Engl J Med"},{"key":"2199_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1109\/TMI.2014.2303821","volume":"33","author":"G Litjens","year":"2014","unstructured":"Litjens G, Debats O, Barentsz J, Karssemeijer N, Huisman H (2014) Computer-aided detection of prostate cancer in MRI. IEEE Trans Med Imaging 33:1083\u20131092","journal-title":"IEEE Trans Med Imaging"},{"key":"2199_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM et al (2020) Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 296:76\u201384","journal-title":"Radiology"},{"key":"2199_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eururo.2021.06.026","volume":"80","author":"AJ Vickers","year":"2021","unstructured":"Vickers AJ (2021) Effects of magnetic resonance imaging targeting on overdiagnosis and overtreatment of prostate cancer. Eur Urol 80:567\u2013572","journal-title":"Eur Urol"},{"key":"2199_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2214\/AJR.18.20536","volume":"212","author":"MD Greer","year":"2019","unstructured":"Greer MD, Shih JH, Lay N et al (2019) Interreader variability of Prostate Imaging Reporting and Data System version 2 in detecting and assessing prostate cancer lesions at prostate MRI. AJR Am J Roentgenol 212:1197\u20131205","journal-title":"AJR Am J Roentgenol"},{"key":"2199_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eururo.2020.09.043","volume":"79","author":"V Stavrinides","year":"2021","unstructured":"Stavrinides V, Syer T, Hu Y et al (2021) False positive multiparametric magnetic resonance imaging phenotypes in the biopsy-naive prostate: are they distinct from significant cancer-associated lesions? Lessons from PROMIS. Eur Urol 79:20\u201329","journal-title":"Eur Urol"},{"key":"2199_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76:340\u2013351","journal-title":"Eur Urol"},{"key":"2199_CR9","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1007\/s00330-017-4843-7","volume":"27","author":"L Zhang","year":"2017","unstructured":"Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y (2017) A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol 27:5204\u20135214","journal-title":"Eur Radiol"},{"key":"2199_CR10","doi-asserted-by":"publisher","first-page":"e223128","DOI":"10.1148\/radiol.223128","volume":"307","author":"B Turkbey","year":"2023","unstructured":"Turkbey B, Purysko AS (2023) PI-RADS: where next? Radiology 307:e223128","journal-title":"Radiology"},{"key":"2199_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1148\/radiol.2016152542","volume":"280","author":"AB Rosenkrantz","year":"2016","unstructured":"Rosenkrantz AB, Ginocchio LA, Cornfeld D et al (2016) Interobserver reproducibility of the PI-RADS Version 2 lexicon: a multicenter study of six experienced prostate radiologists. Radiology 280:793\u2013804","journal-title":"Radiology"},{"key":"2199_CR12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/jmri.26555","volume":"49","author":"CP Smith","year":"2019","unstructured":"Smith CP, Harmon SA, Barrett T et al (2019) Intra- and interreader reproducibility of PI-RADSv2: a multireader study. J Magn Reson Imaging 49:1694\u20131703","journal-title":"J Magn Reson Imaging"},{"key":"2199_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","volume":"4","author":"E Mazzone","year":"2021","unstructured":"Mazzone E, Stabile A, Pellegrino F et al (2021) Positive predictive value of Prostate Imaging Reporting and Data System Version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 4:697\u2013713","journal-title":"Eur Urol Oncol"},{"key":"2199_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","volume":"25","author":"B Oerther","year":"2022","unstructured":"Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M (2022) Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis 25:256\u2013263","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2199_CR15","doi-asserted-by":"publisher","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2024) Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.035","DOI":"10.1016\/j.eururo.2024.09.035"},{"key":"2199_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","volume":"25","author":"A Saha","year":"2024","unstructured":"Saha A, Bosma JS, Twilt JJ et al (2024) Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol 25:879\u2013887","journal-title":"Lancet Oncol"},{"key":"2199_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41747-022-00288-8","volume":"6","author":"MRS Sunoqrot","year":"2022","unstructured":"Sunoqrot MRS, Saha A, Hosseinzadeh M, Elschot M, Huisman H (2022) Artificial intelligence for prostate MRI: open datasets, available applications, and grand challenges. Eur Radiol Exp 6:35","journal-title":"Eur Radiol Exp"},{"key":"2199_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2214\/AJR.21.26917","volume":"219","author":"B Turkbey","year":"2022","unstructured":"Turkbey B, Haider MA (2022) Artificial intelligence for automated cancer detection on prostate MRI: opportunities and ongoing challenges, from the AJR Special Series on AI Applications. AJR Am J Roentgenol 219:188\u2013194","journal-title":"AJR Am J Roentgenol"},{"key":"2199_CR19","doi-asserted-by":"publisher","unstructured":"Nketiah GA, Sunoqrot MR, Sandsmark E et al (2024) Deep radiomics detection of clinically significant prostate cancer on multicenter MRI: initial comparison to PI-RADS assessment. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2410.16238","DOI":"10.48550\/arXiv.2410.16238"},{"key":"2199_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41591-021-01312-x","volume":"27","author":"E Wu","year":"2021","unstructured":"Wu E, Wu K, Daneshjou R, Ouyang D, Ho DE, Zou J (2021) How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals. Nat Med 27:582\u2013584","journal-title":"Nat Med"},{"key":"2199_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41746-021-00549-7","volume":"5","author":"AAH de Hond","year":"2022","unstructured":"de Hond AAH, Leeuwenberg AM, Hooft L et al (2022) Guidelines and quality criteria for artificial intelligence-based prediction models in healthcare: a scoping review. NPJ Digit Med 5:2","journal-title":"NPJ Digit Med"},{"key":"2199_CR22","unstructured":"EUR-Lex (2024) EUR-Lex Regulation (EU) 2024\/1689 of the European Parliament and of the Council of 13 June 2024 laying down harmonised rules on artificial intelligence and amending Regulations (EC) No 300\/2008, (EU) No 167\/2013, (EU) No 168\/2013, (EU) 2018\/858, (EU) 2018\/1139 and (EU) 2019\/2144 and Directives 2014\/90\/EU, (EU) 2016\/797 and (EU) 2020\/1828 (Artificial Intelligence Act). Available via https:\/\/eur-lex.europa.eu\/eli\/reg\/2024\/1689. Accessed 4 Mar 2025"},{"key":"2199_CR23","unstructured":"EUR-Lex (2017) EUR-Lex Regulation (EU) 2017\/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and repealing Council Directives 90\/385\/EEC and 93\/42\/EEC (Text with EEA relevance). Available via https:\/\/eur-lex.europa.eu\/eli\/reg\/2017\/745. Accessed 12 Jun 2025"},{"key":"2199_CR24","unstructured":"U.S. FDA (2017). FDA guidance document software as a medical device (SAMD): clinical evaluation guidance for industry and Food and Drug Administration staff. Available via https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/software-medical-device-samd-clinical-evaluation. Accessed 12 Jun 2025"},{"key":"2199_CR25","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ et al (2020) The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87\u2013e99","journal-title":"Am J Surg Pathol"},{"key":"2199_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1148\/radiol.2015151516","volume":"277","author":"Bossuyt","year":"2015","unstructured":"Bossuyt, Reitsma PM, Bruns DE JB et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 277:826\u2013832","journal-title":"Radiology"},{"key":"2199_CR27","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij M, Israel B, Tummers M et al (2020) ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radiol 30:5404\u20135416","journal-title":"Eur Radiol"},{"key":"2199_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/sim.4780120902","volume":"12","author":"SE Vollset","year":"1993","unstructured":"Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809\u2013824","journal-title":"Stat Med"},{"key":"2199_CR29","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1148\/radiol.229021","volume":"305","author":"D Daye","year":"2022","unstructured":"Daye D, Wiggins WF, Lungren MP et al (2022) Implementation of clinical artificial intelligence in radiology: who decides and how? Radiology 305:E62","journal-title":"Radiology"},{"key":"2199_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.prnil.2022.04.002","volume":"10","author":"A Sosenko","year":"2022","unstructured":"Sosenko A, Owens RG, Yang AL et al (2022) Non-infectious complications following transrectal prostate needle biopsy\u2014outcomes from over 8000 procedures. Prostate Int 10:158\u2013161","journal-title":"Prostate Int"},{"key":"2199_CR31","doi-asserted-by":"publisher","first-page":"111790","DOI":"10.1016\/j.ejrad.2024.111790","volume":"181","author":"N Bayerl","year":"2024","unstructured":"Bayerl N, Adams LC, Cavallaro A et al (2024) Assessment of a fully-automated diagnostic AI software in prostate MRI: clinical evaluation and histopathological correlation. Eur J Radiol 181:111790","journal-title":"Eur J Radiol"},{"key":"2199_CR32","doi-asserted-by":"publisher","unstructured":"Moliere S, Hamzaoui D, Ploussard G et al (2024) A systematic review of the diagnostic accuracy of deep learning models for the automatic detection, localization, and characterization of clinically significant prostate cancer on magnetic resonance imaging. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.11.001","DOI":"10.1016\/j.euo.2024.11.001"},{"key":"2199_CR33","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.euf.2024.04.007","volume":"10","author":"K Guenzel","year":"2024","unstructured":"Guenzel K, Lukas Baumgaertner G, Padhani AR et al (2024) Diagnostic utility of artificial intelligence-assisted transperineal biopsy planning in prostate cancer suspected men: a prospective cohort study. Eur Urol Focus 10:833\u2013842","journal-title":"Eur Urol Focus"},{"key":"2199_CR34","doi-asserted-by":"publisher","first-page":"e232788","DOI":"10.1148\/radiol.232788","volume":"314","author":"YJ Lee","year":"2025","unstructured":"Lee YJ, Moon HW, Choi MH et al (2025) MRI-based deep learning algorithm for assisting clinically significant prostate cancer detection: a bicenter prospective study. Radiology 314:e232788","journal-title":"Radiology"},{"key":"2199_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s41747-024-00529-y","volume":"8","author":"L Rundo","year":"2024","unstructured":"Rundo L, Militello C (2024) Image biomarkers and explainable AI: handcrafted features versus deep learned features. Eur Radiol Exp 8:130","journal-title":"Eur Radiol Exp"},{"key":"2199_CR36","doi-asserted-by":"crossref","unstructured":"Vrettos K, Triantafyllou M, Marias K, Karantanas AH, Klontzas ME (2024) Artificial intelligence-driven radiomics: developing valuable radiomics signatures with the use of artificial intelligence. BJR Artif Intell 1:ubae011","DOI":"10.1093\/bjrai\/ubae011"},{"key":"2199_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/RLI.0000000000000673","volume":"55","author":"JL Wichmann","year":"2020","unstructured":"Wichmann JL, Willemink MJ, De Cecco CN (2020) Artificial intelligence and machine learning in radiology: current state and considerations for routine clinical implementation. Invest Radiol 55:619\u2013627","journal-title":"Invest Radiol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-02199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-025-02199-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-02199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:33:55Z","timestamp":1769430835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-025-02199-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1186\/s13244-025-02199-9","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Norwegian Ethics Committees for Clinical Trials on Medicinal Products and Medical Devices (REK KULMU; identifier no. 479272).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}